Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.
Content published before 2002 is available via pay-per-view purchase only.
Subscribe:
Subscribe to Surgical Oncology ClinicsAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A decade of immune-checkpoint inhibitors in cancer therapy.Nat Commun. 2020; 11: 3801
- A Pilot Study of Anti-CTLA4 Antibody Ipilimumab in Patients with Synovial Sarcoma.Sarcoma. 2013; 2013: 168145
- Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): a multicentre, two-cohort, single-arm, open-label, phase 2 trial.Lancet Oncol. 2017; 18: 1493-1501
- Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): two open-label, non-comparative, randomised, phase 2 trials.Lancet Oncol. 2018; 19: 416-426
- Clinical activity of pembrolizumab (P) in undifferentiated pleomorphic sarcoma (UPS) and dedifferentiated/pleomorphic liposarcoma (LPS): Final results of SARC028 expansion cohorts.Jco. 2019; 37: 11015
- A multicenter phase II study of nivolumab +/- ipilimumab for patients with metastatic sarcoma (Alliance A091401): Results of expansion cohorts.Jco. 2020; 38: 11511
- Angiosarcoma patients treated with immune checkpoint inhibitors: a case series of seven patients from a single institution.J Immunother Cancer. 2019; 7: 213
- Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease.Cold Spring Harb Mol Case Stud. 2019; 5: a004408
- Angiosarcoma treated successfully with anti-PD-1 therapy - a case report.J Immunother Cancer. 2017; 5: 58
- The Angiosarcoma Project: enabling genomic and clinical discoveries in a rare cancer through patient-partnered research.Nat Med. 2020; 26: 181-187
- Multicenter phase II trial (SWOG S1609, cohort 51) of ipilimumab and nivolumab in metastatic or unresectable angiosarcoma: a substudy of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors (DART).J Immunother Cancer. 2021; 9: e002990
- Use of PD-1 Targeting, Macrophage Infiltration, and IDO Pathway Activation in Sarcomas: A Phase 2 Clinical Trial.JAMA Oncol. 2018; 4: 93-97
- Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.Eur J Cancer. 2019; 119: 151-157
- Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft part sarcoma: a single-arm, phase 2 trial.Lancet Oncol. 2019; 20: 837-848
- Nivolumab and sunitinib combination in advanced soft tissue sarcomas: a multicenter, single-arm, phase Ib/II trial.J Immunother Cancer. 2020; 8: e001561
- Apatinib plus camrelizumab (anti-PD1 therapy, SHR-1210) for advanced osteosarcoma (APFAO) progressing after chemotherapy: a single-arm, open-label, phase 2 trial.J Immunother Cancer. 2020; 8
- B cells are associated with survival and immunotherapy response in sarcoma.Nature. 2020; 577: 556-560
- Immunomodulation by radiotherapy in tumour control and normal tissue toxicity.Nat Rev Immunol. 2022; 22: 124-138
- Immunogenic effects of chemotherapy-induced tumor cell death.Genes Dis. 2018; 5: 194-203
- Phase II study of pembrolizumab in combination with doxorubicin in metastatic and unresectable soft tissue sarcoma.Clin Cancer Res. 2021; 27: 6424-6431
- Assessment of Doxorubicin and Pembrolizumab in Patients With Advanced Anthracycline-Naive Sarcoma: A Phase 1/2 Nonrandomized Clinical Trial.JAMA Oncol. 2020; 6: 1778-1782
- Systemic Interferon-γ Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.Cancer Immunol Res. 2019; 7: 1237-1243
- The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors.J Immunother Cancer. 2019; 7: 278
- Clinicopathological and prognostic significance of PD-L1 expression in sarcoma: A systematic review and meta-analysis.Medicine (Baltimore). 2018; 97: e11004
- PD1/PD-L1 targeting in advanced soft-tissue sarcomas: a pooled analysis of phase II trials.J Hematol Oncol. 2020; 13: 55
- Sarcomas: Immune biomarker expression and checkpoint inhibitor trials.Cancer Treat Rev. 2020; 91: 102115
- Correlative Analyses of the SARC028 Trial Reveal an Association Between Sarcoma-Associated Immune Infiltrate and Response to Pembrolizumab.Clin Cancer Res. 2020; 26: 1258-1266
- PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.Jco. 2021; 39: 11507
- Comprehensive and Integrated Genomic Characterization of Adult Soft Tissue Sarcomas.Cell. 2017; 171 (e28): 950.e28
- Comprehensive Analysis of Hypermutation in Human Cancer.Cell. 2017; 171 (e10): 1042.e10
- Characteristics of mismatch repair deficiency in sarcomas.Mod Pathol. 2019; 32: 977-987
- Absence of Microsatellite Instability In Soft Tissue Sarcomas.Pathobiology. 2015; 82: 36-42
- Specific immune landscapes and immune checkpoint expressions in histotypes and molecular subtypes of sarcoma.Oncoimmunology. 2020; 9: 1792036
- Comprehensive profiling of immune-related genes in soft tissue sarcoma patients.J Transl Med. 2020; 18: 337
- Monophasic and biphasic synovial sarcomas abundantly express cancer/testis antigen NY-ESO-1 but not MAGE-A1 or CT7.Int J Cancer. 2001; 94: 252-256
- The cancer-testis antigen NY-ESO-1 is highly expressed in myxoid and round cell subset of liposarcomas.Mod Pathol. 2013; 26: 282-288
- The urgent need to recover MHC class I in cancers for effective immunotherapy.Curr Opin Immunol. 2016; 39: 44-51
- Antitumor Activity Associated with Prolonged Persistence of Adoptively Transferred NY-ESO-1 (c259)T Cells in Synovial Sarcoma.Cancer Discov. 2018; 8: 944-957
Hong, D.S. Phase I dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors. 2020. ASCO Virtual Scientific Program: American Society of Clinical Oncology. J Clin Oncol, 38, no. 15_suppl. 2020. 102-102.
- HLA Genotyping in Synovial Sarcoma: Identifying HLA-A∗02 and Its Association with Clinical Outcome.Clin Cancer Res. 2020; 26: 5448-5455
- Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma.J Immunother Cancer. 2019; 7: 276
- IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A∗02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).Jco. 2021; 39: TPS11582
- MAGE-A4, NY-ESO-1 and SAGE mRNA expression rates and co-expression relationships in solid tumours.BMC Cancer. 2020; 20: 606
- Immunohistochemical expression and clinicopathological assessment of the cancer testis antigens NY-ESO-1 and MAGE-A4 in high-grade soft-tissue sarcoma.Oncol Lett. 2019; 17: 3937-3943
- SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.Jco. 2021; 39: 11504
- CAR T cell immunotherapy for human cancer.Science. 2018; 359: 1361-1365
- Toxicities of chimeric antigen receptor T cells: recognition and management.Blood. 2016; 127: 3321-3330
- The ErbB/HER family of protein-tyrosine kinases and cancer.Pharmacol Res. 2014; 79: 34-74
- Human Epidermal Growth Factor Receptor 2 (HER2) –Specific Chimeric Antigen Receptor–Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma.J Clin Oncol. 2015; 33: 1688-1696
- Abstract LB-147: Administration of HER2-CAR T cells after lymphodepletion safely improves T cell expansion and induces clinical responses in patients with advanced sarcomas.Cancer Res. 2019; 79 (LB-147-LB-147)
- Insulin-like growth factor-I receptor tyrosine kinase inhibitor cyclolignan picropodophyllin inhibits proliferation and induces apoptosis in multidrug resistant osteosarcoma cell lines.Mol Cancer Ther. 2009; 8: 2122-2130
- The Role of IGF/IGF-IR-Signaling and Extracellular Matrix Effectors in Bone Sarcoma Pathogenesis.Cancers (Basel). 2021; 13
- IGF1R- and ROR1-Specific CAR T Cells as a Potential Therapy for High Risk Sarcomas.PLoS One. 2015; 10: e0133152
- CD44/CD44v6 a Reliable Companion in Cancer-Initiating Cell Maintenance and Tumor Progression.Front Cell Dev Biol. 2018; 6: 97
- Prognostic significance of CD44V6 expression in osteosarcoma: a meta-analysis.J Orthop Surg Res. 2015; 10: 187
- CD44v6 as innovative sarcoma target for CAR-redirected CIK cells.Oncoimmunology. 2018; 7: e1423167
- Activated and expanded natural killer cells target osteosarcoma tumor initiating cells in an NKG2D-NKG2DL dependent manner.Cancer Lett. 2015; 368: 54-63
- Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.PLoS One. 2012; 7: e31210
- Memory T Cells Expressing an NKG2D-CAR Efficiently Target Osteosarcoma Cells.Clin Cancer Res. 2017; 23: 5824-5835
- Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.Clin Cancer Res. 2011; 17: 4550-4557
- Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.Clin Cancer Res. 2016; 22: 3734-3745
- Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.Clin Cancer Res. 2013; 19: 4792-4800
- Establishment of adoptive cell therapy with tumor infiltrating lymphocytes for non-small cell lung cancer patients.Cancer Immunol Immunother. 2018; 67: 1221-1230
- Expansion of tumor-infiltrating lymphocytes and their potential for application as adoptive cell transfer therapy in human breast cancer.Oncotarget. 2017; 8: 113345-113359
- Early Cost-Effectiveness Modeling for Tumor Infiltrating Lymphocytes (TIL) -Treatment Versus Ipilimumab in Metastatic Melanoma Patients.Value Health. 2014; 17: A640
- Treatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin 2.J Natl Cancer Inst. 1994; 86: 1159-1166
- High-dose interleukin-2 (IL-2) for the treatment of melanoma: safety considerations and future directions.Expert Opin Drug Saf. 2017; 16: 1347-1357
- Toxicities Associated With Adoptive T-Cell Transfer for Cancer.Cancer J. 2015; 21: 506-509
- Expanded Tumor-infiltrating Lymphocytes From Soft Tissue Sarcoma Have Tumor-specific Function.J Immunother. 2021; 44: 63-70
- Targeting natural killer cells in cancer immunotherapy.Nat Immunol. 2016; 17: 1025-1036
- The Tumor Microenvironment-A Metabolic Obstacle to NK Cells' Activity.Cancers (Basel). 2020; 12
- Prospects for the use of NK cells in immunotherapy of human cancer.Nat Rev Immunol. 2007; 7: 329-339
- Treatment of patients with advanced cancer with the natural killer cell line NK-92.Cytotherapy. 2013; 15: 1563-1570
- Selection of Shared and Neoantigen-Reactive T Cells for Adoptive Cell Therapy Based on CD137 Separation.Front Immunol. 2017; 8: 1211
- Selection of CD8+PD-1+ lymphocytes in fresh human melanomas enriches for tumor-reactive T cells.J Immunother. 2010; 33: 956-964
- Arrested development: suppression of NK cell function in the tumor microenvironment.Clin Transl Immunol. 2021; 10: e1238
- A critical role for natural killer T cells in immunosurveillance of methylcholanthrene-induced sarcomas.J Exp Med. 2002; 196: 119-127
- CAR T Cells in Solid Tumors: Blueprints for Building Effective Therapies.Front Immunol. 2018; 9: 1740
- Objective Response Rate Among Patients With Locally Advanced or Metastatic Sarcoma Treated With Talimogene Laherparepvec in Combination With Pembrolizumab: A Phase 2 Clinical Trial.JAMA Oncol. 2020; 6: 402-408
- The potential of the CMB305 vaccine regimen to target NY-ESO-1 and improve outcomes for synovial sarcoma and myxoid/round cell liposarcoma patients.Expert Rev Vaccin. 2018; 17: 107-114
- A Phase 1b Study Evaluating the Safety, Tolerability, and Immunogenicity of CMB305, a Lentiviral-Based Prime-Boost Vaccine Regimen, in Patients with Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1.Oncoimmunology. 2020; 9: 1847846
- Phase II Randomized Study of CMB305 and Atezolizumab Compared With Atezolizumab Alone in Soft-Tissue Sarcomas Expressing NY-ESO-1.J Clin Oncol. 2021; : Jco2003452https://doi.org/10.1200/JCO.20.03452
- Tumor-associated macrophages and macrophage-related immune checkpoint expression in sarcomas.Oncoimmunology. 2020; 9: 1747340
- The Immunosuppressive Niche of Soft-Tissue Sarcomas is Sustained by Tumor-Associated Macrophages and Characterized by Intratumoral Tertiary Lymphoid Structures.Clin Cancer Res. 2020; 26: 4018-4030
Chawla, S.P., et al. RESULTS FROM THE CHONDROSARCOMA PHASE 1 STUDY EXPANSION COHORT OF THE TETRAVALENT DEATH RECEPTOR 5 AGONIST INBRX-109. in Connective Tissue Oncology Society Annual Meeting. November 19, 2020.
- The treatment of malignant tumors by repeated inoculations of erysipelas. With a report of ten original cases. 1893.Clin Orthop Relat Res. 1893; 1991: 3-11
Kawai, A., et al., Efficacy and safety of nivolumab monotherapy in patietns with unresectable clear cell sarcoma and alveolar soft part sarcoma (OSCAR trial, NCCH1510): A multicenter, Phase 2 clinical trial., in Connective Tissue Oncology Society Annual Meeting. November 19, 2020.
- Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.Jco. 2021; 39: 11564
- A phase II multi-arm study of durvalumab and tremelimumab for advanced or metastatic sarcomas.Jco. 2020; 38: 11509
- Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).Jco. 2021; 39: 11519
- Activity and Safety of Geptanolimab (GB226) for Patients with Unresectable, Recurrent, or Metastatic Alveolar Soft Part Sarcoma: A Phase II, Single-arm Study.Clin Cancer Res. 2020; 26: 6445-6452
- Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.Eur J Cancer. 2020; 130: 182-192
- Combined KIT and CTLA-4 Blockade in Patients with Refractory GIST and Other Advanced Sarcomas: A Phase Ib Study of Dasatinib plus Ipilimumab.Clin Cancer Res. 2017; 23: 2972-2980
- SAINT: Results of a phase 1/2 study of safety/efficacy using safe amounts of ipilimumab, nivolumab, and trabectedin as first-line treatment of advanced soft tissue sarcoma.Jco. 2019; 37: 11016
- IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: Results from the phase II part, bone sarcoma cohort.Jco. 2020; 38: 11522
Article info
Footnotes
C. Moreno Tellez and Y. Leyfman contributed equally to this article as co-first-authors.
Identification
Copyright
© 2022 Elsevier Inc. All rights reserved.
